Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 11 May 2021 Biocartis Receives EUR 1.4m Grant to Support Development of New Idylla™ Technology to Unlock Potential in Molecular Surveillance Non-regulated information 4 May 2021 Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer Non-regulated information 22 April 2021 BIOCARTIS Q1 2021 BUSINESS UPDATE Regulated information 22 April 2021 Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ Inside information Regulated information 20 April 2021 Biocartis Announces US FDA 510(k) submission of its Idylla™ MSI Test Non-regulated information 13 April 2021 Invitation to the Annual and Extraordinary Shareholders’ Meetings Regulated information 1 April 2021 Biocartis Announces Publication of 2020 Annual Report Regulated information 22 March 2021 Biocartis Launches Idylla™ GeneFusion Assay as Rapid Lab Workflow Solution for Gene Fusion Testing Non-regulated information 25 February 2021 BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK Regulated information 18 February 2021 Biocartis Announces 2020 Full Year Results on 25 February 2021 Regulated information Pagination First page « First Previous page ‹‹ … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page ›› Last page Last »